LLY

As of 2026-10-26, LLY scores 63out of 100 on QNTM’s five-factor quantitative model, a high conviction reading. The score blends momentum, quality, volume, value and sentiment, then adjusts for the current macro regime. LLY trades at $1279.14, 8% above the band ceiling.

LLY scores 63 out of 100 on QNTM's five-factor model — a high-conviction reading — 63 puts it among the strongest factor profiles the model tracks. Its strongest factor is quality at 80 (strong), where earnings quality and balance-sheet strength stand out, followed by sentiment at 62. The weakest is volume at 49, where volume gives little confirmation. Among Healthcare stocks it ranks in roughly the top 7% of the Healthcare names the model scores.

On valuation, LLY is priced near the top of its recent range — the rich end on the model's valuation read. The blended composite before the macro overlay was 64. Same-sector names the model rates nearby include HALO, VEEV, THC.

This is a descriptive factor read on LLY, recomputed each trading day and shown with its reasoning — not a recommendation to buy, hold or sell. The score reflects where LLY sits on the model's measures today, and can change as new data arrives.

FACTOR BREAKDOWN

VALUATION RANGE

QNTM’s descriptive fair-value band for LLY runs $842.60–$1186.24. Current price $1279.14 sits 8% above the band ceiling. This is valuation context, not a price target.

OTHER HEALTHCARE NAMES

QNTM provides quantitative model outputs for informational and educational purposes only. It is not investment advice and QNTM is not a registered investment adviser. Scores are rankings, not buy/sell recommendations. Data as of 2026-10-26.